US2013115211A1PendingUtilityA1

Cytokine antagonists for neurological and neuropsychiatric disorders

64
Individually held — no corporate assignee on recordPriority: Feb 24, 1999Filed: Jan 2, 2013Published: May 9, 2013
Est. expiryFeb 24, 2019(expired)· nominal 20-yr term from priority
Inventors:Edward L. Tobinick
A61K 47/6835A61K 2039/505A61P 25/24A61K 47/60A61P 25/18A61P 25/30C07K 2319/32A61P 25/16A61K 38/1793A61P 25/34A61K 47/6811A61K 38/20A61K 39/3955A61P 25/00A61P 25/06C07K 2319/30A61P 25/28C07K 16/241A61K 9/0019
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method, comprising: introducing a therapeutically effective amount of a specific TNF blocker to cerebrospinal fluid of a human in need of treatment for symptoms associated with neronal compression.

Claims

exact text as granted — not AI-modified
1 - 59 . (canceled) 
     
     
         60 . A method, comprising:
 introducing a therapeutically effective amount of a specific TNF blocker to cerebrospinal fluid of a human in need of treatment for symptoms associated with neuronal compression.

Join the waitlist — get patent alerts

Track US2013115211A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.